FRANKFURT, Jan 25 (Reuters) - European regulators approved the sale of Merck KGaA's Rebif treatment for patients with early stage multiple sclerosis, the German company said on Wednesday. The approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results